EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience
| Autor: | Nishi Kothari, Yound Doo Chang, Amit Mahipal, Richard D. Kim, Dae Won Kim, Jennifer Byer |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Leucovorin Cetuximab Irinotecan Metastasis 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Panitumumab Anal cancer Protein Kinase Inhibitors Aged Retrospective Studies EGFR inhibitors business.industry Incidence (epidemiology) Antibodies Monoclonal Retrospective cohort study Chemoradiotherapy General Medicine Middle Aged Anus Neoplasms medicine.disease ErbB Receptors stomatognathic diseases Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Florida Camptothecin Female Fluorouracil Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Oncology. 92:190-196 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Background: Although squamous cell anal carcinomas are relatively rare, their incidence has been increasing steadily. Because of the limited data, treatment of metastatic disease is a major therapeutic challenge. In this study, we report the safety and efficacy of epidermal growth factor receptor (EGFR) inhibitors in patients with advanced squamous cell anal carcinomas. Method: A retrospective analysis was conducted using the Moffitt Cancer Tumor Registry from January 2009 to January 2014. Eligible patients had diagnosis of advanced squamous cell anal carcinomas and received an EGFR inhibitor as part of their treatment. Result: A total of 13 patients were identified for analysis. All of them received concurrent chemoradiation as initial treatment and subsequently had recurrence. Five patients received single agent cetuximab or panitumumab, and the others received cetuximab or panitumumab with irinotecan or FOLFIRI. The objective response rate was 30.8% including 1 complete response, and the disease control rate was 46.2%. With a median follow-up of 9.6 months, the median progression-free survival and median overall survival were 4.4 months and 11.4 months, respectively. Conclusion: Our analysis suggests that EGFR inhibitors have potential efficacy and are reasonably well tolerated in patients with squamous cell anal carcinomas. These findings warrant further evaluation in a large prospective trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|